Minor surgical complications · Percutaneous nephrolithotomy
Topical TXA may leads to lower minor surgical complications compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Unplanned hospitalizations or readmissions · Percutaneous nephrolithotomy
1 finding from 1 review
Length of hospital stay · Percutaneous nephrolithotomy
1 finding from 1 review
Stone‐free rate · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in stone‐free rate compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Thromboembolic events · Percutaneous nephrolithotomy
1 finding from 1 review
Adverse events · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in adverse events compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Secondary interventions · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in secondary interventions compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Major surgical complications · Percutaneous nephrolithotomy
Systemic TXA probably leads to lower major surgical complications compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Minor surgical complications · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in minor surgical complications compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Unplanned hospitalizations or readmissions · Percutaneous nephrolithotomy
It is very uncertain whether systemic TXA changes unplanned hospitalizations or readmissions compared with no TXA (placebo or usual care) (very low certainty).
1 finding from 1 review
Length of hospital stay · Percutaneous nephrolithotomy
1 finding from 1 review
All‐cause mortality at day 28 · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.79 [0.43, 1.44]
Studies not reported
Low
Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in improvement of clinical status (number of participants discharged… compared with saline placebo (low certainty).
1 finding from 1 review
Quality of life · individuals with moderate or severe COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
1 finding from 1 review
OR 4
3 participants
GRADE not reported
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Worsening of clinical status at day 28 (data only available for clinical status worsened on day 7) · individuals with moderate or severe COVID‐19
It is very uncertain whether hyperimmune immunoglobulin from human plasma changes worsening of clinical status at day 28 (data only available for… compared with saline placebo (very low certainty).
1 finding from 1 review
RR 0.85 [0.58, 1.23]
Studies not reported
Very low
Improvement of clinical status · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in improvement of clinical status (number of people discharged from… compared with saline placebo (moderate certainty).
1 finding from 1 review
RR 1.02 [0.97, 1.08]
Studies not reported
Moderate
Quality of life · individuals with moderate or severe COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found